Zuprevo
tildipirosin
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Zuprevo
|
Agency product number |
EMEA/V/C/002009
|
Active substance |
tildipirosin
|
International non-proprietary name (INN) or common name |
tildipirosin
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QJ01FA
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
06/05/2011
|
Contact address |
Wim de Körverstraat 35
5831 AN Boxmeer The Netherlands |
Product information
22/03/2016 Zuprevo - EMEA/V/C/002009 - R/0010
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiinfectives for systemic use
Therapeutic indication
40-mg/ml solution for injection for pigs
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis sensitive to tildipirosin.
The presence of the disease in the herd should be confirmed before metaphylaxis is implemented.
180-mg/ml solution for injection for cattle
For the treatment and prevention of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to tildipirosin.
The presence of the disease in the herd should be confirmed before preventive treatment.